A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis.

Abstract

INTRODUCTION:

We investigated the therapeutic effects of three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT).

METHODS:

Sixty-three HCC patients with PVTT were divided into two groups. Group A (30 patients) was treated with three-dimensional conformal radiotherapy followed by 2-3 series of TACE, while group B (33 patients) was only treated with TACE.

RESULTS:

The 1- and 2-year survival rates of group A were 62.40% and 20.81%, respectively, with a mean survival time of 13.0 months. The 1- and 2-year survival rates of group B were 56.49% and 18.83%, respectively, with a mean survival time of 9.0 months. There were significant differences between the two groups (log-rank chi-square value = 3.950, P = 0.047).

CONCLUSION:

Three-dimensional conformal radiotherapy combined with TACE can significantly improve clinical outcomes in patients with HCC and PVTT compared with TACE alone.

• Authors: Dong-Hui Lu, Zhen-Le Fei, Jun-Ping Zhou, Zong-Tao Hu, Wen-Sheng Hao
• Journal: Journal of medical imaging and radiation oncology (J Med Imaging Radiat Oncol) Vol. 59 Issue 1 Pg. 109-14 (Feb 2015) ISSN: 1754-9485 [Electronic] Australia
• PMID: 25088249 (Publication Type: Controlled Clinical Trial, Journal Article)
• Copyright: © 2014 The Royal Australian and New Zealand College of Radiologists.

Topics

• Carcinoma, Hepatocellular (mortality, therapy)
• Causality
• Chemoembolization, Therapeutic (mortality)
• China (epidemiology)
• Combined Modality Therapy (mortality)
• Comorbidity
• Female
• Humans
• Liver Neoplasms (mortality, therapy)
• Male
• Middle Aged
• Portal Vein
• Prevalence
• Radiotherapy, Intensity-Modulated (mortality)
• Retrospective Studies
• Survival Rate
• Treatment Outcome
• Venous Thrombosis (mortality, therapy)